Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) EBT Margin (2017 - 2026)

Lexaria Bioscience's EBT Margin history spans 10 years, with the latest figure at 7250.67% for Q1 2026.

  • Quarterly results put EBT Margin at 7250.67% for Q1 2026, down 566963.0% from a year ago — trailing twelve months through Feb 2026 was 2570.59% (down 78692.0% YoY), and the annual figure for FY2025 was 1682.58%, down 44651.0%.
  • EBT Margin for Q1 2026 was 7250.67% at Lexaria Bioscience, down from 1543.55% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 460.69% in Q1 2024 to a low of 40659.8% in Q3 2022.
  • The 5-year median for EBT Margin is 2290.25% (2022), against an average of 5172.6%.
  • The sharpest move saw EBT Margin tumbled -4063915bps in 2022, then skyrocketed 3703561bps in 2023.
  • Year by year, EBT Margin stood at 1734.71% in 2022, then surged by 57bps to 748.17% in 2023, then tumbled by -96bps to 1462.95% in 2024, then fell by -6bps to 1543.55% in 2025, then crashed by -370bps to 7250.67% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 7250.67%, 1543.55%, and 2155.31% for Q1 2026, Q3 2025, and Q2 2025 respectively.